Related Experiment Video
Updated: Aug 4, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Chemotherapy in patients with recurrent and progressive central neurocytoma
A A Brandes1, P Amistà, M Gardiman
1Department of Medical Oncology, Azienda Ospedale-Università, Padova, Italy.
Background:
Recurrent central neurocytoma is very rare and to the authors' knowledge data regarding its response to chemotherapy currently are not available.
Methods:
Three patients with progressive neurocytoma received chemotherapy after their informed consent was obtained. Disease recurred in two patients after surgery and radiotherapy and in one patient after surgery. The treatment regimen was comprised of etoposide, 40 mg/m(2)/day, for 4 days; cisplatin, 25 mg/m(2)/day, for 4 days; and cyclophosphamide, 1,000 mg/m(2), on Day 4; this cycle was repeated every 4 weeks.
Results:
Stabilization of disease was observed in 2 patients and complete remission was observed in 1 patient; at last follow-up, these responses had been maintained for 15 months, 18 months, and 36 months, respectively.
Conclusions:
In this small series, this therapeutic regimen led to long term disease reduction, and merits further study.
